Cargando…

The d16HER2 Splice Variant: A Friend or Foe of HER2-Positive Cancers?

Human epidermal growth factor receptor 2 (ERBB2 or HER2) amplification/overexpression is associated with a particularly aggressive molecular subtype of breast cancer (BC), characterized by a poor prognosis, increased metastatic potential, and disease recurrence. As only approximately 50% of HER2-pos...

Descripción completa

Detalles Bibliográficos
Autores principales:	Castagnoli, Lorenzo, Ladomery, Michael, Tagliabue, Elda, Pupa, Serenella M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6678616/ https://www.ncbi.nlm.nih.gov/pubmed/31261614 http://dx.doi.org/10.3390/cancers11070902

Ejemplares similares

The landscape of d16HER2 splice variant expression across HER2-positive cancers
por: Volpi, Chiara Costanza, et al.
Publicado: (2019)

Author Correction: The landscape of d16HER2 splice variant expression across HER2-positive cancers
por: Volpi, Chiara Costanza, et al.
Publicado: (2020)

Pathobiological implications of the d16HER2 splice variant for stemness and aggressiveness of HER2-positive breast cancer
por: Castagnoli, L, et al.
Publicado: (2017)

The Human Splice Variant Δ16HER2 Induces Rapid Tumor Onset in a Reporter Transgenic Mouse
por: Marchini, Cristina, et al.
Publicado: (2011)

Intratumor lactate levels reflect HER2 addiction status in HER2‐positive breast cancer
por: Castagnoli, Lorenzo, et al.
Publicado: (2018)

HER2 Signaling and Breast Cancer Stem Cells: The Bridge behind HER2-Positive Breast Cancer Aggressiveness and Therapy Refractoriness
por: Pupa, Serenella M., et al.
Publicado: (2021)

Inhibition of the Wnt Signalling Pathway: An Avenue to Control Breast Cancer Aggressiveness
por: Castagnoli, Lorenzo, et al.
Publicado: (2020)

Fatty acid synthase as a new therapeutic target for HER2-positive gastric cancer
por: Castagnoli, Lorenzo, et al.
Publicado: (2023)

HER2 Copy Number and Resistance Mechanisms in Patients with HER2-positive Advanced Gastric Cancer Receiving Initial Trastuzumab-based Therapy in JACOB Trial
por: Pietrantonio, Filippo, et al.
Publicado: (2023)

“Omics” and Immunologic Approaches to Optimizing Cure Rates in HER2-Positive Breast Carcinomas
por: Tagliabue, Elda, et al.
Publicado: (2014)

Identification of Relevant Conformational Epitopes on the HER2 Oncoprotein by Using Large Fragment Phage Display (LFPD)
por: Gabrielli, Federico, et al.
Publicado: (2013)

Cancer Stem Cells: Devil or Savior—Looking behind the Scenes of Immunotherapy Failure
por: Castagnoli, Lorenzo, et al.
Publicado: (2020)

Predicting the Efficacy of HER2-Targeted Therapies: A Look at the Host
por: Di Modica, Martina, et al.
Publicado: (2017)

Hormone receptor status influences the impact of body mass index and hyperglycemia on the risk of tumor relapse in early-stage HER2-positive breast cancer patients
por: Ligorio, Francesca, et al.
Publicado: (2021)

HER2 and uPAR cooperativity contribute to metastatic phenotype of HER2-positive breast cancer
por: Chandran, Vineesh Indira, et al.
Publicado: (2015)

HER2-PI9 and HER2-I12: two novel and functionally active splice variants of the oncogene HER2 in breast cancer
por: Hart, Vic, et al.
Publicado: (2021)

The Role of MicroRNAs in HER2-Positive Breast Cancer: Where We Are and Future Prospective
por: Fogazzi, Valentina, et al.
Publicado: (2022)

The Link Between the Microbiota and HER2+ Breast Cancer: The New Challenge of Precision Medicine
por: Di Modica, Martina, et al.
Publicado: (2022)

Expression Profile of Tyrosine Phosphatases in HER2 Breast Cancer Cells and Tumors
por: Lucci, Maria Antonietta, et al.
Publicado: (2010)

HER2 isoforms co-expression differently tunes mammary tumor phenotypes affecting onset, vasculature and therapeutic response
por: Palladini, Arianna, et al.
Publicado: (2017)

ZEB Proteins in Leukemia: Friends, Foes, or Friendly Foes?
por: Soen, Bieke, et al.
Publicado: (2018)

HER2 signaling regulates the tumor immune microenvironment and trastuzumab efficacy
por: Triulzi, Tiziana, et al.
Publicado: (2018)

Loss of HER2 Positivity after Trastuzumab in HER2-Positive Gastric Cancer: Is Change in HER2 Status Significantly Frequent?
por: Ishimine, Yu, et al.
Publicado: (2015)

ERBB2D16 Expression in HER2 Positive Gastric Cancer Is Associated With Resistance to Trastuzumab
por: Wang, Shuo, et al.
Publicado: (2022)

Friend and Foe
Publicado: (1890)

Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients
por: Horimoto, Yoshiya, et al.
Publicado: (2022)

Clinical Significance of HER-2 Splice Variants in Breast Cancer Progression and Drug Resistance
por: Jackson, Claire, et al.
Publicado: (2013)

HER2 splice variants in breast cancer: investigating their impact on diagnosis and treatment outcomes
por: Hart, Vic, et al.
Publicado: (2020)

HER2/positive and HER2/low in inflammatory breast cancer recurrence
por: Movchan, Oleksii Volodimirovich, et al.
Publicado: (2022)

LRRK2 in Infection: Friend or Foe?
por: Herbst, Susanne, et al.
Publicado: (2019)

HER3, p95HER2, and HER2 protein expression levels define multiple subtypes of HER2-positive metastatic breast cancer
por: Lipton, Allan, et al.
Publicado: (2013)

Association of HER1 and HER2 Gene Variants in the Predisposition of Colorectal Cancer
por: Alanazi, Ibrahim O., et al.
Publicado: (2021)

Correlation of HER2, p95HER2 and HER3 Expression and Treatment Outcome of Lapatinib plus Capecitabine in her2-Positive Metastatic Breast Cancer
por: Han, Sae-Won, et al.
Publicado: (2012)

HER2 Heterogeneity Is Associated with Poor Survival in HER2-Positive Breast Cancer
por: Hosonaga, Mari, et al.
Publicado: (2018)

HER2 heterogeneity is a poor prognosticator for HER2-positive gastric cancer
por: Kaito, Akio, et al.
Publicado: (2019)

The impact of HER2-directed targeted therapy on HER2-positive DCIS of the breast
por: Lewis, Gary. D., et al.
Publicado: (2021)

Molecular Basis of HER2-Targeted Therapy for HER2-Positive Colorectal Cancer
por: Yoshikawa, Ayumu, et al.
Publicado: (2022)

Anti-HER2 Drugs for the Treatment of Advanced HER2 Positive Breast Cancer
por: Stanowicka-Grada, Malwina, et al.
Publicado: (2023)

Extracellular Matrix Features Discriminate Aggressive HER2-Positive Breast Cancer Patients Who Benefit from Trastuzumab Treatment
por: Rybinska, Ilona, et al.
Publicado: (2020)

HER2 amplification by next-generation sequencing to identify HER2-positive invasive breast cancer with negative HER2 immunohistochemistry
por: Morsberger, Laura, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_uv6tuc05vnpb8cimdg04dsq42q